IgE BINDING PROTEINS AND USES THEREOF
AssigneesPhylaxis Bioscience, LLC, Inhibrx Biosciences, Inc.
InventorsBryan R. Becklund, Kyle S. Jones, Andrew M. Eckles, Brendan P. Eckelman, Tony Dung-Ling Yao
Life of this patent
Estimating the term…
Abstract
Provided herein are IgE-binding VHH domains, polypeptides, and proteins, and methods of using such IgE-binding polypeptides and proteins to modulate the biological activity of IgE.
Claims50
A VHH domain that binds IgE, comprising a complementarity determining region 1 (CDR1), a complementarity determining region 2 (CDR2), and a complementarity determining region 3 (CDR3) of a VHH that comprises the amino acid sequence of SEQ ID NO:
- 42.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
16-17. (canceled)
(canceled)
19-20. (canceled)
22-23. (canceled)
25-27. (canceled)
30-34. (canceled)
36-40. (canceled)
43-45. (canceled)
(canceled)
49-56. (canceled)
58-66. (canceled)
A polypeptide comprising:
- (a) a VHH domain comprising the amino acid sequence of SEQ ID NO:
- 42;
- (b) a human IgG1 Fc region comprising substitutions S267E and L328F, numbered according to the EU index as in Kabat;
- and
- (c) a polypeptide linker,
- wherein the VHH domain is linked to the human IgG1 Fc region via the polypeptide linker.
A polypeptide consisting of the amino acid sequence of SEQ ID NO:
- 86.
A polypeptide consisting of the amino acid sequence of SEQ ID NO:
- 93.
Dependencies are inferred from the claim text.